Domača stranGNLX • NASDAQ
add
Genelux Corp
2,71 $
Po zaprtju:(0,00 %)0,00
2,71 $
Konec trgovanja: 6. mar., 16:00:09 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
2,69 $
Dnevni razpon
2,58 $ - 2,74 $
Letni razpon
1,99 $ - 8,54 $
Tržna kapitalizacija
121,17 mio. USD
Povprečni obseg
196,11 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | — | — |
Stroški poslovanja | 8,19 mio. | 18,05 % |
Čisti dohodek | −7,95 mio. | −22,93 % |
Čista dobičkovnost prihodkov | — | — |
Earnings per share | −0,21 | −10,53 % |
EBITDA | −8,13 mio. | −18,11 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 20,92 mio. | −38,59 % |
Skupna sredstva | 24,99 mio. | −37,95 % |
Skupne obveznosti | 6,40 mio. | −10,91 % |
Celoten lastniški kapital | 18,59 mio. | — |
Shares outstanding | 37,62 mio. | — |
Razmerje P/B | 5,49 | — |
Donosnost sredstev | −71,58 % | — |
Donosnost kapitala | −89,42 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −7,95 mio. | −22,93 % |
Denar iz dejavnosti | −6,58 mio. | −14,39 % |
Denar iz naložb | 4,72 mio. | 18,26 % |
Denar iz financiranja | 0,00 | — |
Neto sprememba denarnih sredstev | −1,85 mio. | −5,58 % |
Prost denarni tok | −4,10 mio. | −27,13 % |
Vizitka
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Datum ustanovitve
2001
Sedež organizacije
Spletno mesto
Zaposleni
24
